Irritable Bowel Syndrome Clinical Trial
NCT number | NCT02242175 |
Other study ID # | 1-2014-0046 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | September 2014 |
Est. completion date | August 2020 |
Verified date | March 2019 |
Source | Yonsei University |
Contact | Yong Chan Lee, MD |
Phone | 82-2-2228-1960 |
leeyc[@]yuhs.ac | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Irritable bowel syndrome is characterized by abdominal discomfort and bowel habit change. It
is increasing worldwide. But the pathophysiology of the irritable bowel syndrome is not
proven. So, the treatment's target is the relief of the symptoms.
Small intestinal bacterial overgrowth considered as the cause of the irritable bowel
syndrome. Because, it is related to the postprandial abdominal discomfort and the abdominal
discomfort could be relieved after taking antibiotics. There are several diagnostic methods
for small intestinal bacterial overgrowth. hydrogen breath test is non-invasive method for
diagnosis of the small intestinal bacterial overgrowth. But, there is no standardized cut-off
value for the hydrogen breath test. So, we want to compare the hydrogen breath test between
the irritable bowel syndrome patients and normal people. And then, we want to analyze the
efficacy of hydrogen breath test for the diagnosis of irritable bowel syndrome.
Status | Recruiting |
Enrollment | 147 |
Est. completion date | August 2020 |
Est. primary completion date | August 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: 1. over 19 years old, male and female 2. normal people (control group, who has no abdominal symptoms - diarrhea, constipation etc.) 3. irritable bowel syndrome patients (irritable bowel syndrome means that within the last 3 months abdominal discomfort more than three days for a month and satisfies over the below two items) 1) symptom relived after defecation 2) bowel habit change, the times of defecation changed 3) the change of the morphology of the stool Exclusion Criteria: 1. patients who do not agree for participation 2. patients who have history for treatment of irritable bowel syndrome 3. patients who is uncontrolled diabetes mellitus 4. patients who have small bowel or large bowel diseases 5. patients who had surgery for abdomen 6. patients who are taking antibiotics, anti-depressants within 1 week 7. patients who are taking proton pump inhibitors or opioids for analgesics 8. patients who have history of bowel adhesion |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Sevrance hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Yonsei University |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The difference of H2 elevation level through the hydrogen breath test between the irritable bowel syndrome patients and the normal people | The difference of H2 elevation level through the hydrogen breath test between the irritable bowel syndrome patients and the normal people | Within the 24 hours after 8-12 hours fasting | |
Secondary | The difference of methane level through the hydrogen breath test between the irritable bowel syndrome patients and the normal people | Within the 24 hours after 8-12 hours fasting |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |